2.50
Hdl Handle:
http://hdl.handle.net/10033/297195
Title:
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.
Authors:
Yin, Lina; Hu, Qingzhong; Hartmann, Rolf W
Abstract:
Since 2010, six drugs have been approved for the treatment of castration-resistant prostate cancer, i.e., CYP17 inhibitor Abiraterone, androgen receptor antagonist Enzalutamide, cytotoxic agent Cabazitaxel, vaccine Sipuleucel-T, antibody Denosumab against receptor activator of nuclear factor kappa B ligand and radiopharmaceutical Alpharadin. All these drugs demonstrate improvement on overall survival, expect for Denosumab, which increases the bone mineral density of patients under androgen deprivation therapy and prolongs bone-metastasis-free survival. Besides further CYP17 inhibitors (Orteronel, Galeterone, VT-464 and CFG920), androgen receptor antagonists (ARN-509, ODM-201, AZD-3514 and EZN-4176) and vaccine Prostvac, more drug candidates with various mechanisms or new indications of launched drugs are currently under evaluation in different stages of clinical trials, including various kinase inhibitors and platinum complexes. Some novel strategies have also been proposed aimed at further potentiation of antitumor effects or reduction of side effects and complications related to treatments. Under these flourishing circumstances, more investigations should be performed on the optimal combination or the sequence of treatments needed to delay or reverse possible resistance and thus maximize the clinical benefits for the patients.
Affiliation:
Pharmaceutical and Medicinal Chemistry, Saarland University & Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Campus C2-3, Saarbrücken D-66123, Germany. q.hu@mx.uni-saarland.de.
Citation:
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. 2013, 14 (7):13958-78 Int J Mol Sci
Journal:
International journal of molecular sciences
Issue Date:
2013
URI:
http://hdl.handle.net/10033/297195
DOI:
10.3390/ijms140713958
PubMed ID:
23880851
Type:
Article
Language:
en
ISSN:
1422-0067
Appears in Collections:
publications of the department drug design and optimization (HIPS]DDOP)

Full metadata record

DC FieldValue Language
dc.contributor.authorYin, Linaen_GB
dc.contributor.authorHu, Qingzhongen_GB
dc.contributor.authorHartmann, Rolf Wen_GB
dc.date.accessioned2013-08-01T09:32:52Z-
dc.date.available2013-08-01T09:32:52Z-
dc.date.issued2013-
dc.identifier.citationRecent progress in pharmaceutical therapies for castration-resistant prostate cancer. 2013, 14 (7):13958-78 Int J Mol Scien_GB
dc.identifier.issn1422-0067-
dc.identifier.pmid23880851-
dc.identifier.doi10.3390/ijms140713958-
dc.identifier.urihttp://hdl.handle.net/10033/297195-
dc.description.abstractSince 2010, six drugs have been approved for the treatment of castration-resistant prostate cancer, i.e., CYP17 inhibitor Abiraterone, androgen receptor antagonist Enzalutamide, cytotoxic agent Cabazitaxel, vaccine Sipuleucel-T, antibody Denosumab against receptor activator of nuclear factor kappa B ligand and radiopharmaceutical Alpharadin. All these drugs demonstrate improvement on overall survival, expect for Denosumab, which increases the bone mineral density of patients under androgen deprivation therapy and prolongs bone-metastasis-free survival. Besides further CYP17 inhibitors (Orteronel, Galeterone, VT-464 and CFG920), androgen receptor antagonists (ARN-509, ODM-201, AZD-3514 and EZN-4176) and vaccine Prostvac, more drug candidates with various mechanisms or new indications of launched drugs are currently under evaluation in different stages of clinical trials, including various kinase inhibitors and platinum complexes. Some novel strategies have also been proposed aimed at further potentiation of antitumor effects or reduction of side effects and complications related to treatments. Under these flourishing circumstances, more investigations should be performed on the optimal combination or the sequence of treatments needed to delay or reverse possible resistance and thus maximize the clinical benefits for the patients.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to International journal of molecular sciencesen_GB
dc.titleRecent progress in pharmaceutical therapies for castration-resistant prostate cancer.en
dc.typeArticleen
dc.contributor.departmentPharmaceutical and Medicinal Chemistry, Saarland University & Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Campus C2-3, Saarbrücken D-66123, Germany. q.hu@mx.uni-saarland.de.en_GB
dc.identifier.journalInternational journal of molecular sciencesen_GB

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.